Expression of microRNA-195 is transactivated by Sp1 but inhibited by histone deacetylase 3 in hepatocellular carcinoma cells

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1859, Issue 7, 2016, Pages 933-942

  Zhao, Na ^a   Li, Siwen ^a   Wang, Ruizhi ^a   Xiao, Manhuan ^a   Meng, Yu ^a   Zeng, Chunxian ^a   Fang, Jian Hong ^a   Yang, Jine ^a   Zhuang, Shi Mei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

HDAC3; Hepatocellular carcinoma; miR 195; Non coding RNA; Sp1

Indexed keywords

HISTONE DEACETYLASE 3; MICRORNA; MICRORNA 195; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; MIRN195 MICRORNA, HUMAN; SP1 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; CANCER TISSUE; CARCINOMA CELL LINE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME INHIBITION; GENE DELETION; GENE EXPRESSION; GENE SILENCING; HEK293 CELL LINE; HEPG2 CELL LINE; HUH 7 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; REDUCTION; TRANSACTIVATION; TRANSCRIPTION INITIATION SITE; UPREGULATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LIVER TUMOR; METABOLISM; PHYSIOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE;

CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HEP G2 CELLS; HISTONE DEACETYLASES; HUMANS; LIVER NEOPLASMS; MICRORNAS; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED;

EID: 84970004176     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2016.05.006     Document Type: Article

References (38)

1. [1] Ha, M., Kim, V.N., Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15 (2014), 509–524.
2. [2] Ryan, B.M., Robles, A.I., Harris, C.C., Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer 10 (2010), 389–402.
3. [3] Fu, M.G., Li, S., Yu, T.T., Qian, L.J., Cao, R.S., Zhu, H., Xiao, B., Jiao, C.H., Tang, N.N., Ma, J.J., et al. Differential expression of miR-195 in esophageal squamous cell carcinoma and miR-195 expression inhibits tumor cell proliferation and invasion by targeting of Cdc42. FEBS Lett. 587 (2013), 3471–3479.
4. [4] Zhang, Q.Q., Xu, H., Huang, M.B., Ma, L.M., Huang, Q.J., Yao, Q., Zhou, H., Qu, L.H., MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro-Oncology 14 (2012), 278–287.
5. [5] Li, D., Zhao, Y., Liu, C., Chen, X., Qi, Y., Jiang, Y., Zou, C., Zhang, X., Liu, S., Wang, X., et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin. Cancer Res. 17 (2011), 1722–1730.
6. [6] Xu, T., Zhu, Y., Xiong, Y., Ge, Y.Y., Yun, J.P., Zhuang, S.M., MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 50 (2009), 113–121.
7. [7] Ding, J., Huang, S., Wang, Y., Tian, Q., Zha, R., Shi, H., Wang, Q., Ge, C., Chen, T., Zhao, Y., et al. Genome-wide screening reveals that miR-195 targets the TNF-alpha/NF-kappaB pathway by down-regulating IkappaB kinase alpha and TAB3 in hepatocellular carcinoma. Hepatology 58 (2013), 654–666.
8. [8] Maluccio, M., Covey, A., Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J. Clin. 62 (2012), 394–399.
9. [9] Bruix, J., Gores, G.J., Mazzaferro, V., Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63 (2014), 844–855.
10. [10] Liu, M., Jiang, L., Guan, X.Y., The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell 5 (2014), 673–691.
11. [11] Wang, R., Zhao, N., Li, S., Fang, J.H., Chen, M.X., Yang, J., Jia, W.H., Yuan, Y., Zhuang, S.M., MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology 58 (2013), 642–653.
12. [12] Fei, X., Qi, M., Wu, B., Song, Y., Wang, Y., Li, T., MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. FEBS Lett. 586 (2012), 392–397.
13. [13] Tropberger, P., Schneider, R., Scratching the (lateral) surface of chromatin regulation by histone modifications. Nat. Struct. Mol. Biol. 20 (2013), 657–661.
14. [14] Haberland, M., Montgomery, R.L., Olson, E.N., The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10 (2009), 32–42.
15. [15] Weichert, W., Roske, A., Gekeler, V., Beckers, T., Ebert, M.P., Pross, M., Dietel, M., Denkert, C., Rocken, C., Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 9 (2008), 139–148.
16. [16] Weichert, W., Roske, A., Niesporek, S., Noske, A., Buckendahl, A.C., Dietel, M., Gekeler, V., Boehm, M., Beckers, T., Denkert, C., Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 14 (2008), 1669–1677.
17. [17] Weichert, W., Roske, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., Fritzsche, F.R., Niesporek, S., Denkert, C., Dietel, M., et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 98 (2008), 604–610.
18. [18] Fritzsche, F.R., Weichert, W., Roske, A., Gekeler, V., Beckers, T., Stephan, C., Jung, K., Scholman, K., Denkert, C., Dietel, M., et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer, 8, 2008, 381.
19. [19] Krusche, C.A., Wulfing, P., Kersting, C., Vloet, A., Bocker, W., Kiesel, L., Beier, H.M., Alfer, J., Histone deacetylase-1 and-3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat. 90 (2005), 15–23.
20. [20] Weichert, W., Denkert, C., Noske, A., Darb-Esfahani, S., Dietel, M., Kalloger, S.E., Huntsman, D.G., Kobel, M., Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10 (2008), 1021–1027.
21. [21] Weichert, W., HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 280 (2009), 168–176.
22. [22] Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancerRichon, V.M., Sandhoff, T.W., Rifkind, R.A., Marks, P.A., Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 10014–10019.
23. [23] Rice, J.C., Futscher, B.W., Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res. 28 (2000), 3233–3239.
24. [24] Buurman, R., Gurlevik, E., Schaffer, V., Eilers, M., Sandbothe, M., Kreipe, H., Wilkens, L., Schlegelberger, B., Kuhnel, F., Skawran, B., Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 143:811–820 (2012), e811–e815.
25. [25] Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J.C., Fu, K., Marquez, V.E., et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer Cell 22 (2012), 506–523.
26. [26] Hsieh, T.H., Hsu, C.Y., Tsai, C.F., Long, C.Y., Wu, C.H., Wu, D.C., Lee, J.N., Chang, W.C., Tsai, E.M., HDAC inhibitors target HDAC5, upregulate MicroRNA-125a-5p, and induce apoptosis in breast cancer cells. Mol. Ther. 23 (2015), 656–666.
27. [27] Cho, J.H., Dimri, M., Dimri, G.P., MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence. J. Biol. Chem. 290 (2015), 10555–10567.
28. [28] Zhang, X., Chen, X., Lin, J., Lwin, T., Wright, G., Moscinski, L.C., Dalton, W.S., Seto, E., Wright, K., Sotomayor, E., et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 31 (2012), 3002–3008.
29. [29] Jeong, S., Stein, A., Micrococcal nuclease digestion of nuclei reveals extended nucleosome ladders having anomalous DNA lengths for chromatin assembled on non-replicating plasmids in transfected cells. Nucleic Acids Res. 22 (1994), 370–375.
30. [30] Mladenova, V., Mladenov, E., Russev, G., Organization of plasmid DNA into nucleosome-like structures after transfection in eukaryotic cells. Biotechnol. Biotechnol. Equip. 23 (2009), 1044–1047.
31. [31] Suzuki, A., Sanda, N., Miyawaki, Y., Fujimori, Y., Yamada, T., Takagi, A., Murate, T., Saito, H., Kojima, T., Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex. J. Biol. Chem. 285 (2010), 13444–13453.
32. [32] Ye, Y., Jin, L., Wilmott, J.S., Hu, W.L., Yosufi, B., Thorne, R.F., Liu, T., Rizos, H., Yan, X.G., Dong, L., et al. PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat. Commun., 4, 2013, 1508.
33. [33] Aghdassi, A., Sendler, M., Guenther, A., Mayerle, J., Behn, C.O., Heidecke, C.D., Friess, H., Buchler, M., Evert, M., Lerch, M.M., et al. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61 (2012), 439–448.
34. [34] Bolden, J.E., Peart, M.J., Johnstone, R.W., Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006), 769–784.
35. [35] Marks, P.A., Discovery and development of SAHA as an anticancer agent. Oncogene 26 (2007), 1351–1356.
36. [36] Jia, D., Wei, L., Guo, W., Zha, R., Bao, M., Chen, Z., Zhao, Y., Ge, C., Zhao, F., Chen, T., et al. Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology 54 (2011), 1227–1236.
37. [37] Chang, T.C., Yu, D., Lee, Y.S., Wentzel, E.A., Arking, D.E., West, K.M., Dang, C.V., Thomas-Tikhonenko, A., Mendell, J.T., Widespread microRNA repression by Myc contributes to tumorigenesis. Nat. Genet. 40 (2008), 43–50.
38. [38] Deng, H., Guo, Y., Song, H., Xiao, B., Sun, W., Liu, Z., Yu, X., Xia, T., Cui, L., Guo, J., MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene 518 (2013), 351–359.